Bimatoprost Implant (Durysta™)

Durysta (bimatoprost implant) is covered for lowering intraocular pressure in adults (≥18) with open‑angle glaucoma or ocular hypertension, limited to one implant per treated eye (maximum two implants per patient) and excluding re‑treatment of eyes previously treated with Durysta. Coverage requires documentation of the FDA‑approved diagnosis, failure or severe adverse events to at least two ophthalmic prostaglandins AND to at least two ophthalmic agents from two different pharmacologic classes, and that the implant is prescribed by or in consultation with an ophthalmologist.

"Durysta (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension."

Sign up to see full coverage criteria, indications, and limitations.